Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AR mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	MK-5684 Sensitive: C3 – Early Trials MK-5684 Sensitive : C3	MK-5684 Sensitive: C3 – Early Trials MK-5684 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	ARV-110 Sensitive: C3 – Early Trials ARV-110 Sensitive : C3	ARV-110 Sensitive: C3 – Early Trials ARV-110 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D	DZR123 Sensitive: D – Preclinical DZR123 Sensitive : D
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	docetaxel Resistant: D – Preclinical docetaxel Resistant : D	docetaxel Resistant: D – Preclinical docetaxel Resistant : D
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D	5-fluorouracil Resistant: D – Preclinical 5-fluorouracil Resistant : D